FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023530149> ?p ?o ?g. }

• W2023530149 endingPage "500" @default.
• W2023530149 startingPage "498" @default.
• W2023530149 abstract "Time for primary review 3 days. See article by Workman et al. [5] (pages 518–525) in this issue. Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia found in clinical practice. AF is a supraventricular tachyarrhythmia characterised by uncoordinated atrial activation with consequent deterioration of atrial mechanical function [1]. The ventricular response to AF depends on the electrophysiological properties of the atrio-ventricular (AV) node, the level of vagal or sympathetic tone, and the action of drugs with which the patient is being treated [2]. Very often, AF occurs in conjunction with other cardiovascular diseases, such as hypertension, ischaemic heart disease, valve disease, or cardiac failure. However, in a certain percentage of patients (20–50%) AF is not associated with any underlying pathology [3]. Treatment with β-blockers is considered to be efficacious for controlling the ventricular heart rate during AF, which is likely due to the ability of these drugs to depress the conduction velocity through the AV node. Moreover, in patients with adrenergically mediated AF, β-blockers represent a first-line treatment [4]. However, the underlying mechanism of action of β-blockers in human atrial fibrillation has not been established. In fact, the mechanisms by which most cardioactive drugs are effective in clinical practice are unknown, despite the knowledge of their effects on ionic currents, receptors, signal transduction, etc. Indeed, there is an important gap of knowledge that involves drug effects on the target cells; atrial myocytes from patients with AF, in this case. In this regard, different ethical and technical problems have limited these studies.In the present issue of Cardiovascular Research, Workman et al. [5] present experimental evidence of an electrical remodelling in human atrial cells from patients chronically treated with β-blockers, the so-called ‘pharmacological remodelling’, consistent with a partial … *Tel.: +34-91-384-1474; fax: +34-91-394-1470." @default.
• W2023530149 created "2016-06-24" @default.
• W2023530149 creator A5062893427 @default.
• W2023530149 date "2003-06-01" @default.
• W2023530149 modified "2023-10-03" @default.
• W2023530149 title "Pharmacological electrical remodelling in human atria induced by chronic β-blockade" @default.
• W2023530149 cites W1430322293 @default.
• W2023530149 cites W1628979938 @default.
• W2023530149 cites W1966526405 @default.
• W2023530149 cites W1967004379 @default.
• W2023530149 cites W1985547906 @default.
• W2023530149 cites W2000752865 @default.
• W2023530149 cites W2003013939 @default.
• W2023530149 cites W2007751518 @default.
• W2023530149 cites W2031780493 @default.
• W2023530149 cites W2049993408 @default.
• W2023530149 cites W2059364171 @default.
• W2023530149 cites W2062206620 @default.
• W2023530149 cites W2063344460 @default.
• W2023530149 cites W2078125895 @default.
• W2023530149 cites W2082510854 @default.
• W2023530149 cites W2102664563 @default.
• W2023530149 cites W2107213822 @default.
• W2023530149 cites W2108247599 @default.
• W2023530149 cites W2119905314 @default.
• W2023530149 cites W2137850358 @default.
• W2023530149 cites W2144928224 @default.
• W2023530149 cites W2152017096 @default.
• W2023530149 cites W2152673194 @default.
• W2023530149 cites W2167331238 @default.
• W2023530149 cites W2169679878 @default.
• W2023530149 doi "https://doi.org/10.1016/s0008-6363(03)00370-5" @default.
• W2023530149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12798421" @default.
• W2023530149 hasPublicationYear "2003" @default.
• W2023530149 type Work @default.
• W2023530149 sameAs 2023530149 @default.
• W2023530149 citedByCount "3" @default.
• W2023530149 countsByYear W20235301492012 @default.
• W2023530149 countsByYear W20235301492014 @default.
• W2023530149 crossrefType "journal-article" @default.
• W2023530149 hasAuthorship W2023530149A5062893427 @default.
• W2023530149 hasBestOaLocation W20235301491 @default.
• W2023530149 hasConcept C126322002 @default.
• W2023530149 hasConcept C164705383 @default.
• W2023530149 hasConcept C170493617 @default.
• W2023530149 hasConcept C2778468042 @default.
• W2023530149 hasConcept C71924100 @default.
• W2023530149 hasConceptScore W2023530149C126322002 @default.
• W2023530149 hasConceptScore W2023530149C164705383 @default.
• W2023530149 hasConceptScore W2023530149C170493617 @default.
• W2023530149 hasConceptScore W2023530149C2778468042 @default.
• W2023530149 hasConceptScore W2023530149C71924100 @default.
• W2023530149 hasIssue "3" @default.
• W2023530149 hasLocation W20235301491 @default.
• W2023530149 hasLocation W20235301492 @default.
• W2023530149 hasOpenAccess W2023530149 @default.
• W2023530149 hasPrimaryLocation W20235301491 @default.
• W2023530149 hasRelatedWork W2011347913 @default.
• W2023530149 hasRelatedWork W2049397185 @default.
• W2023530149 hasRelatedWork W2051519978 @default.
• W2023530149 hasRelatedWork W2073151595 @default.
• W2023530149 hasRelatedWork W2074833529 @default.
• W2023530149 hasRelatedWork W2125804349 @default.
• W2023530149 hasRelatedWork W2159512267 @default.
• W2023530149 hasRelatedWork W2304633692 @default.
• W2023530149 hasRelatedWork W2399063111 @default.
• W2023530149 hasRelatedWork W4245785827 @default.
• W2023530149 hasVolume "58" @default.
• W2023530149 isParatext "false" @default.
• W2023530149 isRetracted "false" @default.
• W2023530149 magId "2023530149" @default.
• W2023530149 workType "article" @default.